Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 17/2023

07.09.2023 | Research

A deep learning approach based on multi-omics data integration to construct a risk stratification prediction model for skin cutaneous melanoma

verfasst von: Weijia Li, Qiao Huang, Yi Peng, Suyue Pan, Min Hu, Pu Wang, Yuqing He

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 17/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Skin cutaneous melanoma (SKCM) is a highly aggressive melanocytic carcinoma whose high heterogeneity and complex etiology make its prognosis difficult to predict. This study aimed to construct a risk subtype typing model for SKCM.

Methods

The study proposes a deep learning framework combining early fusion feature autoencoder (AE) and late fusion feature AE for risk subtype prediction of SKCM. The deep learning framework integrates mRNA, miRNA, and DNA methylation data of SKCM patients from The Cancer Genome Atlas (TCGA), and clusters the screened multi-omics features associated with survival prognosis to identify risk subtypes. Differential expression analysis and functional enrichment analysis were performed between risk subtypes, while SVM classifiers were constructed between differentially expressed genes (DEGs) obtained by Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression screening and risk subtype labels inferred from multi-omics data, and the predictive robustness of risk subtypes inferred from the risk subtype classification prediction model was validated using two independent datasets.

Results

The deep learning framework that combined early fusion feature AE with late fusion feature AE distinguished the two best risk subtypes compared to the multi-omics integration approach with single strategy AE or PCA. A promising C-index (C-index = 0.748) and a significant difference in survival (log-rank P value = 4.61 × 10–9) were found between the identified risk subtypes. The DEGs with the top significance values together with differentially expressed miRNAs provided the biological interpretation of risk subtypes on SKCM. Finally, the framework was applied to predict risk subtypes in two independent test datasets of SKCM patients, all of which showed good predictive power (C-index > 0.680) and significant survival differences (log-rank P value < 0.01).

Conclusion

The SKCM risk subtypes identified by integrating multi-omics data based on deep learning can not only improve the understanding of the molecular mechanisms of SKCM, but also provide clinicians with assistance in treatment decisions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Ji Z-H, Ren W-Z, Yang S et al (2022) Identification of immune-related biomarkers associated with tumorigenesis and prognosis in skin cutaneous melanoma. Am J Cancer Res 12:1727–1739PubMedPubMedCentral Ji Z-H, Ren W-Z, Yang S et al (2022) Identification of immune-related biomarkers associated with tumorigenesis and prognosis in skin cutaneous melanoma. Am J Cancer Res 12:1727–1739PubMedPubMedCentral
Zurück zum Zitat Meyer D, Dimitriadou E, Hornik K, et al (2014) Misc Functions of the Department of Statistics (e1071), TU Wien Meyer D, Dimitriadou E, Hornik K, et al (2014) Misc Functions of the Department of Statistics (e1071), TU Wien
Zurück zum Zitat Poirion OB, Chaudhary K, Garmire LX (2018) Deep Learning data integration for better risk stratification models of bladder cancer. AMIA Jt Summits Transl Sci Proc 2017:197–206PubMed Poirion OB, Chaudhary K, Garmire LX (2018) Deep Learning data integration for better risk stratification models of bladder cancer. AMIA Jt Summits Transl Sci Proc 2017:197–206PubMed
Zurück zum Zitat Team R (2014) R: A language and environment for statistical computing. MSOR connections Team R (2014) R: A language and environment for statistical computing. MSOR connections
Metadaten
Titel
A deep learning approach based on multi-omics data integration to construct a risk stratification prediction model for skin cutaneous melanoma
verfasst von
Weijia Li
Qiao Huang
Yi Peng
Suyue Pan
Min Hu
Pu Wang
Yuqing He
Publikationsdatum
07.09.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 17/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05358-x

Weitere Artikel der Ausgabe 17/2023

Journal of Cancer Research and Clinical Oncology 17/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.